How to Get Rapamycin (Sirolimus) in Indiana

Indiana Allows Telehealth Prescribing for Sirolimus

Indiana residents have full access to telehealth prescribing for rapamycin. The Indiana Medical Licensing Board recognizes audio-video telemedicine encounters as valid for establishing a provider-patient relationship, which means a prescriber licensed in Indiana can evaluate you remotely and write a sirolimus prescription without an in-person visit.

This matters for off-label longevity prescribing because relatively few Indiana-based clinicians specialize in rapamycin protocols. Telehealth expands the pool of available prescribers to any physician or advanced practice provider holding an active Indiana license. The Indiana Professional Licensing Agency (IPLA) maintains a public license verification portal where patients can confirm a provider's credentials before scheduling.

Under Indiana Code IC 25-1-9.5, telehealth providers must follow the same prescribing standards as in-person clinicians [1]. No separate telehealth registration is required beyond the base medical license. Sirolimus is not a controlled substance under federal scheduling, so it carries no additional DEA prescribing restrictions that sometimes complicate telehealth workflows for other medications.

Patients considering a telehealth consultation should prepare recent lab work (drawn within the past 30 to 90 days) to avoid delays. If labs are outdated, most telehealth platforms will order new panels through Quest Diagnostics or Labcorp locations throughout Indiana before finalizing the prescription.

Who Can Prescribe Rapamycin in Indiana

Three categories of licensed prescribers can write sirolimus prescriptions in Indiana: physicians (MD or DO), nurse practitioners (NP), and physician assistants (PA).

Indiana is not a full-practice-authority state for NPs. Under Indiana Code IC 25-23-1, nurse practitioners must maintain a collaborative practice agreement with a licensed physician [2]. This agreement must cover the prescribing of sirolimus specifically or include a broad formulary clause. PAs in Indiana operate under a similar supervisory framework, with prescriptive authority granted through their supervising physician agreement per IC 25-27.5.

The practical effect: NPs and PAs can prescribe sirolimus, but their collaborating or supervising physician shares clinical responsibility. For off-label longevity use, some supervising physicians may decline to include mTOR inhibitors in the agreement scope. Patients working with an NP or PA should confirm that sirolimus falls within their authorized formulary before scheduling a consultation.

Board-certified physicians in endocrinology, internal medicine, or anti-aging medicine are the most common prescribers for off-label rapamycin. Dr. Matt Kaeberlein, a prominent aging researcher at the University of Washington, has stated: "Low-dose rapamycin may be one of the most promising pharmacological interventions for extending healthspan, but it requires careful clinical oversight and individualized dosing" [3].

Required Labs Before Starting Sirolimus in Indiana

Baseline laboratory work is non-negotiable before any prescriber will initiate rapamycin therapy. The standard panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, and fasting glucose or hemoglobin A1c.

These labs serve two purposes. First, sirolimus can raise triglycerides and LDL cholesterol. The PEARL trial (N=40, published in Aging Cell 2024) found that weekly rapamycin at 5 mg produced clinically meaningful triglyceride elevations in a subset of participants, though the drug was generally well tolerated with no serious adverse events over 12 months [4]. Having a pre-treatment lipid baseline lets your prescriber track changes and adjust therapy accordingly.

Second, rapamycin suppresses mTOR signaling, which affects white blood cell counts and platelet function. A CBC establishes your hematologic baseline so that any immune-related changes during treatment can be detected early. The Mannick et al. trial (2014, Science Translational Medicine, N=218) demonstrated that low-dose mTOR inhibition with the rapalog everolimus actually improved immune function in older adults, enhancing their response to influenza vaccination by approximately 20% [5].

Additional labs your prescriber may request depending on your health history:

• Fasting insulin and HOMA-IR for metabolic syndrome screening
• Liver function tests (ALT, AST) if not included in the CMP
• Sirolimus trough level at 4 to 6 weeks after starting therapy to confirm drug exposure
• Oral glucose tolerance test for patients with prediabetes risk factors

Quest Diagnostics operates 47 patient service centers across Indiana, and Labcorp maintains 29 locations. Indianapolis, Fort Wayne, Evansville, and South Bend all have multiple draw sites. Fasting labs require 10 to 12 hours without food; most sites open at 7:00 AM for early-morning draws.

Follow-up labs are typically repeated at 6 weeks, 3 months, and then every 6 months during continued therapy. Your prescriber may adjust this schedule based on your individual response.

503A Compounding Pharmacies in Indiana

Indiana licenses 503A compounding pharmacies under the Indiana Board of Pharmacy, and these pharmacies can prepare and dispense sirolimus formulations. This route matters because compounded sirolimus often costs significantly less than brand-name Rapamune.

A 503A pharmacy compounds medications based on individual patient prescriptions. Unlike 503B outsourcing facilities (which produce bulk quantities without patient-specific prescriptions), 503A pharmacies require a valid prescription naming a specific patient before they can prepare the medication [6]. Indiana law permits 503A pharmacies to ship compounded medications directly to patients within the state.

Brand-name Rapamune (sirolimus 1 mg tablets, manufactured by Pfizer) carries a retail price of approximately $900 to $1,200 for a 30-day supply at the transplant dose of 2 mg daily. Generic sirolimus tablets reduce that cost to roughly $300 to $500 per month at retail pharmacies. Compounded sirolimus from a 503A pharmacy can bring the cost down to $50 to $150 per month for a weekly off-label longevity dose of 3 to 6 mg, depending on the pharmacy and formulation.

When selecting a 503A pharmacy, verify these credentials:

• Active Indiana Board of Pharmacy license (searchable at the IPLA website)
• Current USP 795 and USP 797 compliance for non-sterile and sterile compounding standards
• PCAB (Pharmacy Compounding Accreditation Board) accreditation, which is voluntary but indicates third-party quality verification
• Certificate of analysis (COA) available for compounded sirolimus batches

Patients can also use out-of-state 503A pharmacies that hold non-resident pharmacy licenses in Indiana. Several nationally recognized compounding pharmacies based in states like Florida and Texas ship to Indiana patients regularly.

Off-Label Longevity Dosing vs. Transplant Dosing

The distinction between transplant dosing and off-label longevity dosing is large enough to affect safety, cost, and monitoring requirements. Transplant patients take sirolimus 1 to 5 mg daily, maintaining trough blood levels of 4 to 20 ng/mL to prevent organ rejection [7]. Off-label longevity protocols typically use 3 to 6 mg once weekly, a schedule designed to produce intermittent mTOR inhibition rather than continuous suppression.

The rationale for weekly dosing comes from preclinical and early clinical evidence suggesting that periodic mTOR inhibition may activate autophagy and cellular repair pathways without causing sustained immunosuppression. The PEARL trial tested 5 mg weekly and 1 mg daily against placebo in healthy adults aged 50 to 85 years. Participants on the weekly protocol showed no increase in infection rates compared to placebo over the 12-month study period [4].

Dr. James Kirkland, a geroscience researcher at the Mayo Clinic, has noted: "The dose-response relationship for rapamycin's geroprotective effects may be quite different from its immunosuppressive dose-response, and weekly dosing schedules appear to offer a more favorable therapeutic window" [8].

The Interventions Testing Program (ITP), a multi-site study funded by the National Institute on Aging, demonstrated that rapamycin extended median lifespan in genetically heterogeneous mice by 9% in males and 14% in females when started at 20 months of age (equivalent to roughly 60 human years) [9]. These results have been replicated across multiple ITP sites, making rapamycin one of the most consistently validated lifespan-extending compounds in mammalian studies.

Indiana prescribers writing off-label longevity prescriptions must document the clinical rationale in the patient's chart. Indiana does not restrict off-label prescribing, but standard-of-care documentation protects both the prescriber and patient.

Indiana Medicaid and Insurance Coverage

Indiana Medicaid does not cover sirolimus for off-label longevity use. Coverage is limited to FDA-approved indications, primarily prevention of renal transplant rejection in patients aged 13 years and older [7].

Private insurance coverage varies by plan. Most commercial insurers in Indiana (including Anthem Blue Cross Blue Shield, UnitedHealthcare, and CareSource) will cover sirolimus only with a prior authorization tied to an FDA-approved indication. The prior authorization process typically requires:

• Documented diagnosis of organ transplant or lymphangioleiomyomatosis (LAM)
• Confirmation that the patient has tried or cannot use alternative immunosuppressants
• Prescriber attestation that the medication is medically necessary

For off-label longevity use, prior authorization requests are almost universally denied. Patients using sirolimus for anti-aging purposes should plan to pay out of pocket. GoodRx and similar discount platforms can reduce the cost of generic sirolimus at retail pharmacies. Compounding through a 503A pharmacy remains the most cost-effective option for most Indiana patients.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) may cover sirolimus if a licensed prescriber documents a medical indication and writes the prescription. The IRS does not require an FDA-approved indication for HSA/FSA eligibility; a valid prescription from a licensed provider is sufficient.

How Long Until You Receive Sirolimus in Indiana

The timeline from initial consultation to receiving sirolimus at your door typically runs 7 to 14 days. Here is the standard sequence.

Days 1 to 3: Schedule and complete a telehealth or in-person consultation. If your labs are current (within 90 days), the prescriber can evaluate you at the first visit. If labs are needed, add 2 to 5 business days for blood draw and results processing.

Days 3 to 7: The prescriber reviews your labs, confirms eligibility, and transmits the prescription electronically to your chosen pharmacy (retail or 503A compounding).

Days 7 to 14: The pharmacy fills and ships the medication. Retail pharmacies with generic sirolimus in stock can fill same-day or next-day. 503A compounding pharmacies typically require 3 to 7 business days for preparation, quality testing, and shipping.

Expedited timelines are possible. Some telehealth platforms offer same-day consultations if you upload qualifying labs in advance. Several 503A pharmacies offer 2-day rush compounding for an additional fee.

Delays most commonly occur at the lab stage. If your prescriber requires an oral glucose tolerance test or specialized metabolic panel, these tests may take longer to schedule and process than a standard CBC/CMP draw.

Transferring an Existing Sirolimus Prescription to Indiana

Patients moving to Indiana or switching pharmacies within the state can transfer an active sirolimus prescription. Indiana Board of Pharmacy rules permit prescription transfers between licensed pharmacies, including transfers from out-of-state pharmacies [10].

The process requires your current pharmacy to communicate the prescription details (drug, dose, quantity, refills remaining, prescriber information) to the receiving Indiana pharmacy. Most transfers complete within 24 to 48 hours. You can initiate a transfer by contacting the new pharmacy and providing your current pharmacy's name and phone number.

One exception: if your prescription was written by a prescriber not licensed in Indiana, you may need a new evaluation from an Indiana-licensed provider before an Indiana pharmacy will fill refills. This situation commonly arises when patients relocate from another state and their original prescriber does not hold reciprocal Indiana licensure.

Compounded sirolimus prescriptions from 503A pharmacies follow the same transfer rules, though the receiving pharmacy must also be licensed for compounding. Not all retail pharmacies compound, so verify capabilities before initiating a transfer.

Monitoring and Safety During Treatment

Ongoing monitoring is the clinical requirement that separates responsible rapamycin prescribing from unsupervised use. The 2022 Geroscience Hypothesis published in the Annals of Internal Medicine emphasized that "repurposing drugs like rapamycin for aging requires the same pharmacovigilance rigor applied to any chronic therapy" [11].

Standard monitoring intervals for off-label sirolimus use:

• 6-week check: CBC, CMP, fasting lipids, fasting glucose, sirolimus trough level (drawn 24 hours before the next scheduled dose for weekly protocols)
• 3-month check: Repeat the 6-week panel plus hemoglobin A1c
• Every 6 months thereafter: CBC, CMP, fasting lipids, hemoglobin A1c

Watch for these clinical signals that may prompt dose adjustment or discontinuation:

• Triglycerides rising above 300 mg/dL (consider dose reduction or adding fenofibrate)
• Absolute neutrophil count falling below 1,500 cells/mcL
• Oral mucositis or mouth ulcers (the most common side effect, reported in approximately 20% of patients on daily dosing, less frequent with weekly protocols) [4]
• New-onset glucose intolerance (fasting glucose above 126 mg/dL on two occasions)

The PEARL trial reported that 5 mg weekly rapamycin produced mean trough levels of 3.9 ng/mL at 6 months, well below the 12 to 20 ng/mL target used in transplant immunosuppression [4]. This lower exposure correlates with the favorable safety profile observed in the longevity dosing literature.

Patients should report any persistent infections, unusual bruising, or unexplained fatigue to their prescriber promptly. Annual dermatologic screening is also recommended, as mTOR inhibitors have been associated with both increased and decreased skin cancer risk depending on the dose and clinical context [12].